What Researchers Did
This review article examined the role of tumour hypoxia in radiotherapy outcomes and summarized the rationale and results of clinical trials using hypoxic sensitizers or cytotoxins for head and neck carcinoma.
What They Found
Researchers found that tumour hypoxia is a significant factor contributing to radioresistance, with low oxygen concentrations linked to poor local-regional control. Early 1970s hyperbaric oxygen trials improved local control and survival rates in head and neck cancer patients receiving radiotherapy, but later trials of nitro-imidazoles, including a 298-patient RTOG trial and a 626-patient Danish trial, yielded inconclusive results.
What This Means for Canadian Patients
This review highlights the persistent challenge of tumour hypoxia in effectively treating head and neck cancer with radiotherapy. While some approaches like hyperbaric oxygen showed early promise, the inconclusive results for newer sensitizers suggest that optimizing strategies to overcome hypoxia remains an important area for improving patient outcomes.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
As a review article, this study's findings are limited by the scope and quality of the clinical trials and evidence available up to 1996.